TrialStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2024

[Standard-of-care systemic therapy with or without SBRT in patients with oligoprogressive breast cancer or NSCLC (CURB oligoprogression): an open-label, randomised, controlled, phase 2 study].

Florian Stritzke et al.PubMed ↗Publisher ↗

No numbers read from the abstract.